Skip to main content

Drug Testing

Positive tests for non-prescribed use of fentanyl and opioids, as well as heroin, increased during the early months of the COVID-19 pandemic, according to a recently published study of nearly 900,000 de-identified lab results conducted by Quest Diagnostics. Use of fentanyl in combination with other drugs also surged.
The addition of recovery coaching and the use of a digital breathalyzer test were found to reduce participant attrition rates in an outpatient SUD treatment program.
Public health risk is forcing addiction treatment programs to rethink their typical approaches to patient drug testing at this time.
A speaker at this spring's Rx Drug Abuse & Heroin Summit discusses the latest national data on emerging drug threats, highlighting the need to focus on stimulant trends.
A newly published Millennium Health report suggests that worrisome methamphetamine trends need to be on the entire field's radar.
Back to Top